Delivering Gene Therapy’s Promise
To improve the lives of children with CNS diseases
Click to learn more
Lysogene’s determination to succeed is rooted in our deep understanding of the impact central nervous system (CNS) diseases have on patients and families, and springs from our founder whose own child was affected by a neurodegenerative disease.
About Lysogene
Our best-in-class technology

Pioneering Gene Therapies for CNS Disorders

我们先进的基因治疗技术亚搏全站app下载pitalizes on our differentiated knowledge of direct-to-brain administration of AAV vectors, allowing us to precisely target the causes of disease.

Our technology
Our robust pipeline

Extraordinary progress in developing therapies for CNS diseases with lead programs in neurodegenerative lysosomal storage disorders.

yabo app

Transforming the Lives
of Patients and Families

Our team is committed to developing pioneering therapies that will transform the lives of children affected by these devastating diseases.

Clinical Trials

Transforming the Lives
of Patients and Families

Our team is committed to fulfilling gene therapy’s potential by developing pioneering therapies that will transform the lives of children affected by these devastating diseases.

Clinical Trials

LatestNews

News, press releases, and more.

Lysogene Provides Clinical Update on AAVance Phase 2/3 Clinical Trial with Gene Therapy LYS-SAF302 for the Treatment of MPS IIIA at the 25th Annual ASGCT Meeting

 Lysogene Provides Clinical Update on AAVance Phase 2/3 Clinical Trial with Gene Therapy LYS-SAF302 for the Treatment of MPS IIIA at the 25th Annual ASGCT Meeting150150Lysogene

• Promising efficacy data in young patients with persistent increase or stabilization in 3 main…

Lysogene Reports its Cash Position as of 31 March 2022

 Lysogene Reports its Cash Position as of 31 March 2022150150Lysogene

Cash and cash equivalents of €10.7 million[1] as of 31 March 2022 Paris, France —…

Lysogene Publishes Positive Preliminary Preclinical Results in the Treatment of Fragile X Syndrome

 Lysogene Publishes Positive Preliminary Preclinical Results in the Treatment of Fragile X Syndrome150150Lysogene

Paris, France — 21 April 2022 at 08:00 am CEST — Lysogene (FR0013233475 – LYS),…

Lysogene Announces Filing of 2021 Universal Registration Document

 Lysogene Announces Filing of 2021 Universal Registration Document150150Lysogene

Paris, France — 20 April 2022 at 08:00 am — Lysogene (FR0013233475 – LYS), a…

Lysogene Enters into an Exclusive Worldwide License Agreement with Yeda, the commercial arm of the Weizmann Institute of Science, for a Novel Gene Therapy Candidate for Neuronopathic Gaucher Disease and Parkinson Disease with GBA1 Mutations

 Lysogene Enters into an Exclusive Worldwide License Agreement with Yeda, the commercial arm of the Weizmann Institute of Science, for a Novel Gene Therapy Candidate for Neuronopathic Gaucher Disease and Parkinson Disease with GBA1 Mutations150150Lysogene

Lysogene exercises its option after a conclusive research collaboration period Paris, France — 12 April 2022…

Lysogene Reports Full Year 2021 Financial Results

 Lysogene Reports Full Year 2021 Financial Results150150Lysogene

Paris, France – 31 March 2022 at 8:00 am CET – Lysogene (FR0013233475 – LYS),…

Lysogene Provides Update on Efficacy, Safety and Timelines of the AAVance phase 2/3 clinical trial with gene therapy LYS-SAF302 for the treatment of MPSIIIA

 Lysogene Provides Update on Efficacy, Safety and Timelines of the AAVance phase 2/3 clinical trial with gene therapy LYS-SAF302 for the treatment of MPSIIIA150150Lysogene

Topline data of the main cohort of AAVance clinical trial expected in Q3 2022 Stabilization…

Lysogene Reports Additional Positive Biomarker data with LYS-SAF302 and Favorable Safety data with LYS-GM101 presented at the WORLDSymposium™ 2022

 Lysogene Reports Additional Positive Biomarker data with LYS-SAF302 and Favorable Safety data with LYS-GM101 presented at the WORLDSymposium™ 2022150150Lysogene

New positive biomarker data from 16 patients treated with LYS-SAF302 showing reduction in heparan sulfate…

Lysogene Provides Medical Update

 Lysogene Provides Medical Update150150Lysogene

Third patient treated in the global clinical trial with LYS-GM101 gene therapy program in GM1…

Lysogene Reports its Cash Position as of 31 December 2021

 Lysogene Reports its Cash Position as of 31 December 2021150150Lysogene

Cash and cash equivalents of €12.3 million[1] as of 31 December 2021 Paris, France —…

All News

Diseases

Valuable information designed to provide knowledge and insights to patients, families, and caregivers.

MPS IIIA
亚博登录首页
Fragile X
Gaucher & Parkinson's
MPS IIIA

Mucopolysaccharidosis type IIIA (MPS IIIA), or Sanfilippo syndrome type A, is a rare neurodegenerative lysosomal storage disorder characterized by intractable behavioral problems and developmental regression that typically appears in infancy or early childhood.

Learn more
亚博登录首页

亚博登录首页GM1 gangliosidosis或降落的疾病,是一种罕见的inherited neurodegenerative lysosomal storage disorder characterized by severe cognitive and motor developmental delays.

Learn more
Fragile X

Fragile X syndrome (FXS) is the most common inherited cause of autism spectrum disorder and affects approximately 1 in 4,000 to 5,000 boys and 1 in 8,000 girls.

Learn more
Gaucher & Parkinson's

Neuronopathic Gaucher and Parkinson’s disease are both associated with mutations in the GBA1 gene and cause neurological symptoms.

Learn more

Company Award for Innovation

The EURORDIS Company Award for Innovation recognizes Lysogene as a pioneering gene therapy company which has established itself among major players driving European-led innovation, in just over ten years.

#EURORDISAWARDS2022

Lysogene COVID-19 update

Find out More

Lysogene is developing therapies for children with CNS diseases.

Delivering Gene Therapy’s Promise

About Us
Our Science
Meet the Team
Diseases
Resources

Contact Us
Careers
Transparency
Compassionate Use Policy

©2022 Lysogene. All rights reserved.

Cookie Policy
Privacy Policy
Legal Notice

Get In Touch

Don’t hesitate to contact us if you need more help.

    Start Typing